Merz Pharma France v Viatris Santé (CFI, 30 July 2026)
| Date | 30 July 2026 |
|---|---|
| Court | CFI |
| Division | Paris (FR) Local Division |
| Type of action | Infringement Action |
| Case number(s) | UPC_CFI_1901/2026 |
| Registry reference | UPC-CFI-0001901/2026 |
| Parties | Merz Pharma France, Merz Therapeutics GmbH, Merz Pharmaceuticals LLC v. Viatris Santé |
Official decision (PDF) · UPC registry entry
Case timeline
- 15 October 2026 : Merz Pharma France v Viatris Santé (CFI, 15 October 2026) UPC-CFI-0001901/2026
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 30 July 2026, the Paris Local Division dismissed Viatris Santé’s preliminary objection in the infringement action brought by three Merz companies on the basis of French supplementary protection certificate No. 13C0033, derived from EP 2 377 536. Viatris had asked the UPC to decline jurisdiction in favour of the Paris Judicial Court or, failing that, to stay the proceedings. The order is a useful guide to how the UPC deals with a national court seised first of a revocation and non-infringement action concerning the same right.
Question
Must the UPC decline jurisdiction or stay its proceedings, on grounds of lis pendens or related actions (Articles 29 and 30 of Regulation 1215/2012) or under Rule 295, where the defendant has previously brought an action for revocation of the SPC and a declaration of non-infringement before the Paris Judicial Court?
Decision
The objection was filed in time and was admissible. The Paris Judicial Court, seised on 16 April 2026, was seised before the UPC merits action of 28 May 2026, the separate and now closed provisional measures proceedings did not fix the date of seisure. Article 29 nevertheless did not apply, since the actions lacked the same subject matter and cause of action: infringement on one side, revocation, non-infringement and a compulsory licence on the other. The actions were related, but Article 30 is discretionary: the UPC expected to rule before the national court (oral hearing by May 2027 at the latest), Viatris had itself chosen the national forum and withdrawn its validity challenge before the Court of Appeal, and a stay would unduly delay the proceedings. A stay under Rule 295(b) and (m) was refused for the same reasons. Costs were reserved for the main proceedings.
Key points for practice
- A national action for revocation and non-infringement does not share the subject matter of a UPC infringement action: Article 29 lis pendens does not apply, and relatedness under Article 30 does not compel a stay.
- An earlier application for provisional measures before the UPC does not count as seisure for the merits action.
Provisions applied
- Agreement on a Unified Patent Court
- Arts 31, 32(1)(a), 60(8), 62(5), 63(1) and 83
- Rules of Procedure
- Rules 19.1(a), 20.1, 21.1, 220.2 and 295(b) and (m)
- Regulation (EU) No 1215/2012
- Arts 29, 30, 31(2) and 32
- Other provisions
- French Intellectual Property Code, Art. L. 615-9
- Case law cited
- Merz Pharmaceuticals v Viatris Santé, Court of Appeal, 27 April 2026, Mala v Nokia, Court of Appeal, 17 September 2024, Aylo v Dish, Court of Appeal, 3 September 2024, CJEU, 12 March 2026, Winderwill, C-516/24
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Patent infringement action, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction, The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantMerz Pharma France7 decisions in the corpusFollow this party
- claimantMerz Therapeutics GmbH7 decisions in the corpusFollow this party
- claimantMerz Pharmaceuticals LLC8 decisions in the corpusFollow this party
- defendantViatris Santé7 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
- 30 July 2026 Merz Pharma France v Viatris Santé (CFI, 30 July 2026) Infringement Action · UPC_CFI_1901/2026
- 15 October 2026 Merz Pharma France v Viatris Santé (CFI, 15 October 2026) Infringement Action · UPC_CFI_1901/2026
La division locale de Paris renvoie la demande reconventionnelle en nullité de Viatris à la division centrale de Paris, qui statuera aussi sur le sursis, et poursuit l’action en contrefaçon de Merz.
What the record states
- Nature of the act
- Infringement Action
- Outcome (Dhenne Avocats summary)
- La division locale de Paris rejette l'exception préliminaire de Viatris : pas de litispendance faute d'identité d'objet, et la connexité avec l'action en nullité pendante devant le tribunal judiciaire de Paris ne justifie ni dessaisissement ni sursis.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 2 377 536mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Merz Pharmaceuticals v Viatris Santé (CoA, 27 April 2026) cited in this record
- Mala v Nokia (CoA, 17 September 2024) cited in this record
- AYLO Premium v DISH Technologies (CoA, 3 September 2024) cited in this record
- Merz Pharma France v Viatris Santé (CFI, 15 October 2026) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 377 536Methods of Using Sustained Release Aminopyridine Compositions recorded proprietor: Acorda Therapeutics Inc | Mentioned in the analysis (role not qualified) Also mentioned in 6 other decision(s): Merz Pharmaceuticals v Viatris Santé (CoA, 27 April 2026) · Gowling WLG v Merz Therapeutics (CFI, 19 February 2026) · Merz Pharmaceuticals v Viatris Santé (CoA, 26 January 2026) · Viatris Santé v Merz Pharmaceuticals (CoA, 19 December 2025) · Merz Therapeutics v Viatris Santé (CFI, 17 September 2025) · Merz Pharma France v Viatris Santé (CFI, 15 October 2026) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.